North America Therapeutic Drug Monitoring Market

North America Therapeutic Drug Monitoring Market Size (2023 to 2028)

The market size for therapeutic drug monitoring in the North American region was worth USD 0.62 billion in 2023. This value is further estimated to grow at a CAGR of 6.74% from 2023 to 2028 and a value of USD 0.87 billion by 2028.

The increasing preference for precision medicine drives the market forward. Precision medicine is an approach to the treatment of disease and prevention of the disease. Precision medicine chooses medicines for patients based on disease conditions and medical reports. Oncology has more advantages based on this type of medicine. For example, according to several studies, cancer patients require a combination of drugs for treatment. As a result, this approach is used to test in various settings for treating cancer and other diseases.

An increase in the geriatric population is another factor that drives the market forward. In 2020, nearly 727 million people over the age of 65. The senior population is predicted to reach 17% by 2050. This is due to the older population being at risk of bacterial infections, neurological disorders, autoimmune diseases, and respiratory conditions. Elderly patients are at high risk of developing conditions like chronic obstructive pulmonary disease, adult-onset asthma, multiple sclerosis (MS), and tuberculosis (TB) increases. Additionally, the elderly population is at a higher risk of problems and adverse drug reactions, making therapeutic drug monitoring important.

Due to the growth in disposable income and urbanization, more people are following a sedentary lifestyle. This increases lifestyle diseases such as obesity, hypertension, cardiovascular disorders, and diabetes. Around 9.8% of adults worldwide have diabetes, and 39% of adults are overweight. Furthermore, estimated to affect 26% of people and is predicted to affect 29% of people by 2025. In addition, the number of cardiac arrhythmias increases as the disease is strongly impacted by diabetes and hypertension.

Autoimmune diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), are treated using Anti-TNF-alpha biologics. Therefore, the need for a better understanding of potential differences in biosimilar immunogenicity and their safety and efficacy profiles compared to their precursors has increased with the introduction of biosimilars. As a result, the market is growing due to increasing Anti-arrhythmic drug usage. 

The demand for high-end dialysis equipment has grown as a result of an increase in organ transplant procedures, a focus on research and development, increased use of therapeutic drug monitoring across various therapeutic fields, increased demand for hospitals and medical care facilities, high usage of the drug monitoring test across various therapeutic domains, improvements in the medical industry, growth in awareness, technological advancements, and increased investment by pharmaceutical companies. In hospitals, therapeutic drug monitoring is used to enhance patient quality of life by optimizing the therapeutic benefits of medication and reducing its hazardous side effects.

High capital investments, low returns in research and development, stringent regulatory framework, high infrastructure costs and lack of skilled resources, availability of alternatives, and the refusal of small hospitals to offer TDM services are the factors restraining the market growth.

This research report on the North American therapeutic drug monitoring market has been segmented and sub-segmented into the following categories.

By Product:

• Consumable

• Equipment

By Technology:

• Fluorescence Immunoassay

• Radioimmunoassay

• GCMS

By Drug Class:

• Antiepileptics

• Antibiotics

• Psychoactive Drugs

• Antiarrhythmic Drugs

• Bronchodilators

• Immunosuppressants

• Others

By End-User:

• Hospitals

• Commercial/Private Laboratories

• Others

By Country:

• The United States

• Canada

• Rest of North America

North America had the largest share in the global therapeutic drug monitoring market in 2022. Growth in this region is due to increasing healthcare expenditure, increased availability of advanced technology, and increased patient awareness regarding adverse drug reactions (ADR). Increasing adoption of the TDM for assessing the dosage regimen in developing a treatment for various cardiac indications due to the increased rate of cardiac deaths in recent years. The American Heart Association reports that in 2018, almost 92.1 million Americans suffered from cardiovascular diseases, which increased demand for TDM and boosted the regional market.

KEY MARKET PLAYERS:

Companies playing a prominent role in the North American therapeutic drug monitoring market profiled in this report are Abbott Laboratories, Inc., Agilent Technologies, Inc., Alere, Inc., apDia Group, ARK Diagnostics, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, and Grifols, S.A.